TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05327855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPL-0301 Dose 1
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPL-0301 Dose 2
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study: NCT06271304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue blocking eyewear
Description: Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low filtration eyewear
Description: Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
Study: NCT06203197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)
Description: intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
Study: NCT05777317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 kHz SCS
Description: Spinal cord stimulation programmed to a frequency of 10 kHz

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMM alone
Description: Conventional medical management alone
Study: NCT04813952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane inhalant product
Description: The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane inhalant product
Description: The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
Study: NCT04206215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study: NCT04979988

Intervention type: DRUG
Intervention: Lortlatinib
Description: as provided in real world practice
Study: NCT04798248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Momentary Affect Regulation - Safer Sex Intervention (MARSSI)
Description: MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Podcast Health Group
Description: Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
Study: NCT04856982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT04931381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy guided by organoid drug sensitivity test
Description: Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
Study: NCT06359327

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep19 2 mg
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep19 5 mg
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
Study: NCT04714151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.2 mg/day (once daily)
Description: K-877 ER 0.2 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.4 mg/day (once daily)
Description: K-877 ER 0.4 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877 IR 0.2 mg/day (twice daily)
Description: K-877 IR 0.1 mg tablet
Study: NCT05925985

Intervention type: OTHER
Intervention: NA-Observational Registry
Description: NA Observational Registry

Intervention type: OTHER
Intervention: NA-Observational Registry
Description: NA Observational Registry

Intervention type: OTHER
Intervention: NA-Observational Registry
Description: NA Observational Registry
Study: NCT05585775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness for Wellbeing
Description: Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
Study: NCT05245786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging
Study: NCT04785989

Intervention type: OTHER
Intervention: [U-13C]glucose
Description: \[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Intervention type: OTHER
Intervention: [U-13C]glucose
Description: \[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Intervention type: OTHER
Intervention: [U-13C]glucose
Description: \[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Intervention type: OTHER
Intervention: [13C5]glutamine
Description: 6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
Study: NCT06426602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindBEAGLE daily device use
Description: If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
Study: NCT06288932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) Treatment
Description: The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
Study: NCT05638945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED Delirium Screening and Detection Program (ED-DDP)
Description: The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
Study: NCT05216510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
Study: NCT06538558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezampanel
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezampanel
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezampanel
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezampanel
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
Study: NCT06368089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) group
Description: The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization (EM) group
Description: The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
Study: NCT05523674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up exercise
Description: The warm-up exercise will be performed on a treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up exercise
Description: The warm-up exercise will be performed on a treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up exercise with Blood Flow Restriction
Description: The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
Study: NCT05510544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor,G-CSF
Description: G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours.
Study: NCT06522295

Intervention type: DEVICE
Intervention: ultrasonography
Description: Ultrasonographic Measurement of Optic Nerve Sheath Diameter

Intervention type: DEVICE
Intervention: ultrasonography
Description: Ultrasonographic Measurement of Optic Nerve Sheath Diameter
Study: NCT06079320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir
Description: Participants will receive tablets from Day 1 to Day 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets from Day 1 to Day 5
Study: NCT05311319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+TQB2450+Anlotinib
Description: HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+TQB2450+Anlotinib
Description: HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT05482399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Description: Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
Study: NCT05908942

Intervention type: DEVICE
Intervention: Nerve ablation
Description: radiofrequency and phenol ablation of the genicular nerves will be performed

Intervention type: DEVICE
Intervention: Nerve ablation
Description: radiofrequency and phenol ablation of the genicular nerves will be performed
Study: NCT06499246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Parathyroid
Description: Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
Study: NCT04970342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lactose) Capsule
Description: Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lactose) Capsule
Description: Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75 mg Alprazolam Capsule
Description: Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
Study: NCT04186559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Pentoxifylline Gel (Vehicle +PTX)
Description: Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
Study: NCT04970342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (6.18% THC / <0.025% CBD)
Description: Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (0%/ THC / 0% CBD)
Description: Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
Study: NCT04186559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Pentoxifylline Gel (Vehicle +PTX)
Description: Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Placebo Gel (Vehicle)
Description: Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Gel (Vehicle)
Description: Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.